Want to see EDSA full AI Analyst Report?
EDSA Stock Chart & Stats
$5.25
-$0.03(-0.57%)
At close: 4:00 PM EDT
$5.25
-$0.03(-0.57%)
Day’s Range― - ―
52-Week Range$0.72 - $20.32
Previous CloseN/A
Volume52.26K
Average Volume (3M)95.23K
Market Cap
$50.77M
Enterprise Value$43.04
Total Cash (Recent Filing)$10.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.46
Next Earnings
Dec 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding9,633,223
10 Day Avg. Volume58,770
30 Day Avg. Volume95,231
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$21.00Price Target Upside300.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet (no Debt)A near-zero debt position and roughly $12.4M of equity materially reduce solvency and refinancing risk for a clinical-stage biotech. This provides durable financial flexibility to fund R&D and absorb trial timing variability, lengthening runway versus leveraged peers.
Insider-led PIPE FinancingAn insider-led $3.5M PIPE signals committed capital from management and sector-focused investors, improving near-term funding certainty. Durable impact: lowers immediate fundraising pressure, supports execution of ongoing trials, and aligns insiders with long-term program success.
Supportive Exploratory Clinical SignalsExploratory Phase 2/3 analyses showing mortality and kidney outcome improvements suggest biological activity and potential multi-organ benefits. If replicated in confirmatory trials, this raises the program's long-term commercial and partnering prospects across ARDS and acute kidney injury indications.
Bears Say
Sustained Cash BurnConsistent negative operating cash flow near $7.6M TTM means the company must repeatedly access external capital to fund development. Over months, this creates structural dilution risk and forces prioritization of programs if additional financing is delayed or less favorable.
Minimal Revenue; Large LossesThe company remains pre-revenue with negligible product sales and deep net losses, reflecting dependence on clinical milestones rather than operating cash flow. This structural lack of revenue limits options for self-funding and makes long-term viability contingent on successful trials or partner deals.
Equity-heavy Compensation And Plan ExpansionShifting pay toward RSUs and expanding equity plan availability increases potential share issuance and dilution over time. While conserving cash, this structurally raises long-term dilution risk for shareholders and can complicate capital allocation if equity remains the primary compensation and financing tool.
Edesa Biotech News
EDSA FAQ
What was Edesa Biotech’s price range in the past 12 months?
Edesa Biotech lowest stock price was $0.72 and its highest was $20.32 in the past 12 months.
What is Edesa Biotech’s market cap?
Edesa Biotech’s market cap is $50.77M.
When is Edesa Biotech’s upcoming earnings report date?
Edesa Biotech’s upcoming earnings report date is Dec 11, 2026 which is in 122 days.
How were Edesa Biotech’s earnings last quarter?
Currently, no data Available
Is Edesa Biotech overvalued?
According to Wall Street analysts Edesa Biotech’s price is currently Undervalued.
Does Edesa Biotech pay dividends?
Edesa Biotech does not currently pay dividends.
What is Edesa Biotech’s EPS estimate?
Edesa Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Edesa Biotech have?
Edesa Biotech has 9,633,223 shares outstanding.
What happened to Edesa Biotech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Edesa Biotech?
Currently, no hedge funds are holding shares in EDSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edesa Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.00 (300.00% Upside)
$21.00 (300.00% Upside)
Blogger Sentiment
Bullish
EDSA Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
118.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.73%
Trailing 12-Months
Company Description
Edesa Biotech
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
EDSA Stock 12 Month Forecast
Average Price Target
$21.00
▲(300.00% Upside)
Technical Analysis
Instil Bio
―
TScan Therapeutics
―
MiNK Therapeutics
―
Xilio Therapeutics
―
Tevogen Bio Holdings
―
Ownership Overview
21.62% Insiders
1.30% Mutual Funds
<0.01% Other Institutional Investors
76.23% Public Companies and
Individual Investors